CLINICAL_TRIALS
trial_result
· 2019-01-07
Clinical Trial Update: Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study [Phase 3]
Summary
Phase 3 trial EVOLVE-2 evaluated galcanezumab for prevention of episodic migraine; results were posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2019-01-07